Efficacy of the newest COX-2 selective inhibitors in rheumatic disease

Current Pharmaceutical Design

Volumn 13, Issue 22, 2007, Pages 2228-2236

  Baraf, Herbert S B ^a  

^a Center for Rheumatology and Bone Research   (United States)

Author keywords

COX 2 selective inhibitors; Etoricoxib; Lumiracoxib; Rheumatic disease

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ETORICOXIB; IBUPROFEN; INDOMETACIN; INFLIXIMAB; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; PARECOXIB; PLACEBO; ROFECOXIB; VALDECOXIB;

ANKYLOSING SPONDYLITIS; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIGESTIVE SYSTEM PERFORATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; EDEMA; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GOUT; HUMAN; HYPERTENSION; LIVER TOXICITY; LOW BACK PAIN; LOW DRUG DOSE; NAUSEA AND VOMITING; NEPHROTOXICITY; OSTEOARTHRITIS; PAIN ASSESSMENT; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIDE EFFECT; THROMBOSIS; TOOTH PAIN; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, GOUTY; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; GASTROINTESTINAL HEMORRHAGE; HUMANS; MEMBRANE PROTEINS; OSTEOARTHRITIS; PATIENT SELECTION; PYRIDINES; RHEUMATIC DISEASES; RISK ASSESSMENT; RISK FACTORS; SPONDYLITIS, ANKYLOSING; SULFONES;

EID: 34548210999     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781368819     Document Type: Review

References (91)

1. Cryer B, Feldman, M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413-21.
2. Hochberg M. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Clin Exper Rheumatol 2001; 19 (6 Suppl. 25): S15-S22.
3. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. 2002 Update. Arthritis Rheum; 46: 328-46.
4. Schnitzer T, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. Lancet 2004; 364: 665-74.
5. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with-rheumatoid arthritis. N Engl J Med 2000; 343; 1520-8.
6. Sikes D, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002; 14: 1101-11.
7. Pavelka K, Reeker DP, Verburg KM. Valdecaxib is a effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers, results of a 26 week trial. Rheumatol 2003; 42: 1207-15.
8. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 2006; 119: 255-66.
9. Hunt R, Harper S, Watson DJ, Yu C, Quan H, Lee M, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98: 1725-33.
10. Wong J, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2746-49.
11. Centers for Disease Control. Prevalence of Self-Reported Arthritis or Chronic Joint Symptoms Among Adults. United States, 2001. MMWR 2002; 51: 948-950.
12. Gabriel S, Crowson CS, Luthra HS, Wagner JL, O'Fallon WM. Modeling the lifetime costs of rheumatoid arthritis. Rheumatology 1999; 26: 1269-74.
13. Langman M, Kahler KH, Kong SX, Zhang Q, Finch E, Bentkover JD, et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: A retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf 2001; 10: 517-24.
14. Zhao S, Arguelles LM, Dedhiya SD, Morgan DG. Healthcare utilization associated with dyspepsia in patients with arthritis. Am J Manag Care 1999; 5: 1285-95.
15. Stephens J, Bell CF, Wong JM, Pena BM, Haider S, Pashos CL. Value of cyclooxygenase-2 specific inhibitors in the management of osteoarthritis. Exp Rev Pharmacoeconomics Outcomes Res 2004; 4: 441-55.
16. Bresalier R, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102.
17. Solomon S, McMurray JVJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352: 1071-1080
18. EMEA. European Medicines Agency concludes action on COX-2 inhibitors. London, 27 June 2005 Doc. Ref. EMEA/207766/2005. http://www.emea.eu.int/pdfs/human/press/20776605en.pdf Accessed 3 February 2006.
19. EMEA. European Medicines Agency announces regulatory action on COX-2 inhibitors. 17 February 2005. Doc. Ref: EMEA/62757/2005. http://www.emea.eu.int/htms/hotpress/d6275705.htm. Accessed March 2006.
20. Jenkins JK, Seligman PJ. Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. http://www/fda.gov/cder/drug/inforpage/COX2/NSAIDdecisionMemo.pdf.
21. Food and Drug Administration. COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Accessed July 5, 2005 http://www.fda.gov/cder/drug/ infopage/COX2/default.htm.
22. Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, et al. on behalf of the BSR Standards, Guidelines and Audit Working Group. BSR guidelines for prescribing TNF-a blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatol 2005; 44: 939-47.
23. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005; 64 (Suppl. III): Ii74-7.
24. Hochberg M. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Semin Arthritis Rheum 2002; 32(3, Suppl. 1): 4-14.
25. Kean W, Buchanan WW. The use of NSAIDs in rheumatic disorders 2005: A global perspective. Inflammopharmacology 2005; 13: 343-70.
26. Moore A, Phillips C, Hunsche E, Pellissier J, Crespi S. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. Pharmacoeconomics 2004; 22: 643-60.
27. Hochberg M. COX-2 selective inhibitors in the treatment of arthritis: A theumatologist perspective. Curr Topics Med Chem 2005; 5: 443-8.
28. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/ perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-9.
29. Hernandez-Diaz S, Garcia-Rodriguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 2001; (110 Suppl 3A): 20S-7S.
30. Bingham CO. Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis. Cleveland Clinic J Med 2002; 69 (Suppl. 1): S15-12.
31. Wolfe M, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888-1899.
32. Chen L-C, Elliott RA, Ashcroft DM. Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control. J Clin Pharm Therapeutics 2004; 29: 215-29.
33. Matsumoto A, Cavanaugh PF. Etoricoxib. Drugs of Today 2004; 40: 395-414.
34. Schnitzer T, Hochberg MC. COX-2-selective inhibitors in the treatment of arthritis. Cleveland Clinic J Med 2002; 69 (Suppl. 1): S120-30.
35. Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A, et al. Results of a randomized, dose-ranging trial of etori-coxib in patients with osteoarthritis. Rheumatol. 2002; 41: 1052-1061.
36. Leung AT, Malmstrom K, Gallacher AE, Sarembock B, Poor G, Beaulieu A, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoardiritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trail. Curr Med Res Opin. 2002; 18(2): 49-58.
37. Reginster JY, Malmstrom K, Mehta A, Bergman, G, Ko AT, Curtis, SP, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomized studies of osteoarthritis patients. Ann Rheum Dis. 2006; Online ahead of print: 1-21.
38. Hunsche E, Kong SX, Watson DJ. Impact of etoricoxib, a novel COX-2 inhibitor, on social and emotional quality of life in patients with osteoarthritis. Osteoporosis Intl 2002; 13(Suppl. 3): 20.
39. Hunsche E, Kong SY, Watson DJ. Improvement of physical finctioning in patients with osteoarduitis treated with etoricoxib, naproxen, and placebo: Results from two double-blind, randomized clinical trials. Ann Rheum Dis 2002; 61 (Suppl. 1): 112.
40. Zacher J, Feldman D, Gerli R, Scott D, Hou SM, Uebelhart D, et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin 2003; 19: 725-36.
41. Bingham III CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, et al. Efficacy and safety of etoricoxib 30 ing and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatol 2007; 46: 496-507.
42. Wiesenhutter C, Boice JA, Ko A, Sheldon EA, Murphy FT, Wittmer BA, et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. Mayo Clin Pro 2005; 80: 470-9
43. Curtis SP, Losada B, Bosi-Ferraz M, Saenz R, Miller ER, Ray P, et al. Etoricoxib and diclofenac demonstrate similar efficacy in a 174-week randomized study of rheumatoid arthritis patients. Arthritis Rheum 2003; 48(9):213.
44. Coltantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Family Practice 2002; 3: 1-10.
45. Matsumoto A, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatology 2002; 29: 1623-30
46. Matsumoto A, Zhao PL, Cichanowitz N, Melian A. Etoricoxib is efficacious in patients with rheumatoid arthritis (RA) on concomitant therapy with disease modifying antirheumatic drugs (DMARDs), and/or low-dose corticosteroids. Arthritis Rheum 2003; 48 (Suppl.): S123.
47. Schumacher Jr HR, Boice JA, Kaikh DI, Mukhopadhyay S, Malmstrom K, Ng J, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. Br Med J 2002; 324: 1488-92.
48. Rubin B, Burton R, Navarra S, Antigua J, Londono J, Pryhuber KG, et al. Efficacy and safety profile of treatment with etoricoxib 120 ing once daily compared with indomethacin 50 mg three times daily in acute gout. Arthritis Rheum 2004; 50: 598-606.
49. van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver AL, Schiff M, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52: 1205-15.
50. Pittman J, Bross MH. Diagnosis and management of gout. Am Fam Physician 1999; 59: 1799-1806.
51. Mansour K Cheema GS, Naguwa SM, Greenspan A, Borchers AT, Keen CL, et al. Ankylosing spondylitis: A contemporary perspective on diagnosis and treatment. Semin Arthritis Rheum. 2007; 36(4): 210-223.
52. Gossec L, van der Heijde D, Melian A, Knipa DA, James MK, Cavanaugh PF, et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005; 64: 1563-7.
53. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoardiritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet. 2006 Nov 18; 368(9549): 1771-81.
54. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet 2007; 369: 465-73.
55. Baraf HSB, Fuentealba C, Greenwald M, Brzezicki J, O'Brien K, Soffer B, et al. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: Results of the etoricoxib versus Diclofenac sodium gastrointestinal tolerability and effectiveness (EDGE) trial. J Rheumatol 2007; 34: 408-20.
56. Ramey D, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDS: An updated combined analysis. Curr Med Res Opin 2005; 21: 715-22.
57. Watson D, Bolognese JA, Yu C, Krupa D, Curtis S. Use of gastro-protective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDS. Curr Med Res Opin 2004; 20: 1899-1908.
58. Curtis S, Ng J, Yu Q, Shingo S, Bergman G, McCormick CL, Reicin AS. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004; 26: 70-83.
59. Bannwarth B, Berenbaum F. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor. Expert Opin Investig Drugs 2005; 14: 521-33.
60. Mysler E. Lumiracoxib (Prexig®): A new selective COX-2 inhibitor. J Clin Pract 2004; 58: 606-11.
61. Feret B. Lumiracoxib. A COX-2 inhibitor for the treatment of arthritis and acute pain. Formulary 2003; 38: 528-36.
62. Lyseng-Williamson K, Curran M. Lumiracoxib. Drugs 2004; 64; 2237-46.
63. Berenbaum F, Grifka J, Brown JP, Zacher J, Moore A, Krammer G, Duttta D et al. Efficacy of lumiracoxib in osteoarthritis: A review of nine studies. J Int Med Res 2005; 33: 21-41.
64. Bitner M, Kattenhorn J, Hatfield C, Gan J, Kellstein D. Efficacy and tolerability of lumiracoxib in the treatmentof primary dysmenorrhoea. Int J Clin Pract 2004; 58: 340-5.
65. Zelenakas K, Fricke Jr JR, Jayawardene S, Kellstein D. Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain. Int J Clin Pract 2004; 58: 251-6.
66. Kellstein D, Ott D, Fricke Jr JR. Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain. Int J Clin Pract 2004; 58: 244-50.
67. Schnitzer T, Beier J, Geusens P, Hasler P, Patel SK, Senftleber I, et al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 51: 549-57.
68. Tannenbaum H, Berenbaum F, Reginster JY, Zacher J, Robinson J, Poor G, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: A 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis 2004; 63: 1419-26.
69. Fleischmann R, Sheldon E, Maldonado-Cocco J, Dutta D, Yu S, Sloan VS. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib. Clin Rheum 2006; 25: 42-53.
70. Lehmann R, Brzosko M, Kopsa P, Nischik R, Kreisse A, Thurston H, et al. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: A 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr Med Res Opin 2005; 21: 517-26.
71. Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin Ther 2005; 27: 64-77.
72. Grifka J, Zacher J, Brown JP, Seriolo B, Lee A, Moore A, et al. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand. Clin Exp Rheumatol 2004; 22: 589-96.
73. Geusens P, Alten R, Rovensky J, Sloan VS, Krammer G, Kralidis G, et al. Efficacy safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. Int J Clin Pract 2004; 58: 1033-41.
74. Pavelka K, Nayiager S, Kivitz A, Patel N, Yu S, Sloan V. Efficacy and tolerability of lumiracoxib in the treatment of rheumatoid arthritis: A 13-week, randomized, double-blind study. Ann Rheum Dis 2004; 63(Suppl. 1): 280-81.
75. Farkouh M, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: Randomised controlled trial. Lancet 2004; 364: 675-84.
76. Jones BJP, Lewis JA, Ebbutt AF. Trials to assess equivalence: The importance of rigorous methods. BMJ 1996; 313: 36-9.
77. Boelsterli U. Diclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 2003; 192: 307-22
78. Tang W. The metabolism of diclofenac-enzymology and toxicology perspectives. Curr Drug Metab 2003; 4: 319-29.
79. Physicians' Desk Reference. 60th ed. Montvale, New Jersey; Thomson PDR, 2006.
80. Kivitz A, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther 2004; 19: 1189-98.
81. Chang D, Desjardins PJ, King TR, Erb T, Geba GP. The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: A randomized, double-blind clinical trial. Anesth Analg 2004; 99: 807-15.
82. Malmstrom K, Ang J, Fricke JR, Shingo S, Reicin A. The analgesic effect of etoricoxib relative to that of acetaminophen analgesics: A randomized, controlled single-dose study in acute dental impaction pain. Curr Med Res Opin 2005; 21: 141-9.
83. Malmstrom K, Kotey P, Coughlin H, Desjardins PJ. A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model. Clin Pain J 2004; 20: 147-55.
84. Ciccone D, Just N, Bandilla EB, Reimer E, Ilbeigi MS, Wu W. Psychological correlates of opioid use in patients with chronic nonmalignant pain: A preliminary test of the downhill spiral hypothesis. J Pain Symptom Manage 2000; 20: 180-92.
85. Sproule B, Busto UE, Somer G, Romach MK, Sellers EM. Characteristics of dependent and nondependent regular users of codeine. J Clin Psychopharmacol 1999; 19: 367-72.
86. Arthritis and Allied Conditions, A Textbook of Rheumatology. 15th Edition; William J. Koopman and Larry W. Moreland, Editors Philadelphia, PA, Lippincott Williams & Wilkins, 2004.
87. Raskin J. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 1999; 106(Suppl. 5B): 3S-12S.
88. Chan V, Clark AJ, Davis JC, Wolf RS, Kellstein D, Jayawardene S. The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty. Acta Anaesthesiol Scand 2005; 49: 1491-1500.
89. de Vries EF. Imaging of cyclooxygenase-2 (COX-2) expression: Potential use in diagnosis and drug evaluation. Curr Pharm Des 2006; 12(30): 3847-56.
90. Kurtais Y, Kutlay S, Ergin S. Exercise and cognitive-behavioural treatment in fibromyalgia syndrome. Curr Pharm Des 2006; 12(1): 37-45
91. Lee Y, Rodriguez C, Dionne RA. The role of COX-2 in acute pain and the use of selective COX-2 inhibitors for acute pain relief. Curr Pharm Des 2005; 11(14): 1737-55.